SARS-CoV-2 Drug Discovery Services
SARS-CoV-2 inhibitor screening is an essential part of COVID-19 preclinical drug discovery offered by Reaction Biology. As a CRO (contract research organization) we support the drug discovery community in the challenge to identify efficacious COVID-19 drugs with specific assays for SARS-CoV-2 drug testing with the goal to block virus entry and replication.
Our SARS-CoV-2 drug discovery services are available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.